Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib and Mezigdomide in Relapsed/Refractory Acute Leukemias
NCT07356154Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of revumenib, mezigdomide in acute leukemia, sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2026; status: recruiting.
02
Drugs
revumenibmezigdomide
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT07356154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07356154.